← All indications
Coronary Disease
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
Subtype terms (7)
More specific conditions that are subtypes of Coronary Disease in the MeSH hierarchy.
- Coronary Aneurysm
8 drugs approved
- Coronary Artery Disease
448 drugs (273 approved, 175 experimental)
- Coronary Occlusion
9 drugs (8 approved, 1 experimental)
- Coronary Stenosis
25 drugs (18 approved, 7 experimental)
- Coronary-Subclavian Steal Syndrome
- Coronary Thrombosis
5 drugs (3 approved, 2 experimental)
- Coronary Vasospasm
21 drugs (19 approved, 2 experimental)
Drugs by status
Approved for this indication (10)
Phase 4 trials (98)
- ezetimibe
- propofol
- nitroglycerin
- heparin
- acetylcysteine
- argatroban
- bacille calmette-guerin
- dabigatran
- fimasartan
- cangrelor
- chixiangshen tongxin
- fluvastatin
- laropiprant
- diltiazem
- empagliflozin
- isoflurane
- sevoflurane
- escitalopram
- acarbose
- abciximab
- musk
- amlodipine
- rosuvastatin
- wen xin
- famotidine
- warfarin
- ivabradine
- adenosine
- etomidate
- pitavastatin
- +68 more
Phase 3 trials (66)
- metformin
- edoxaban
- vitamin d3
- vitamin e
- candesartan
- chlorthalidone
- cholestyramine
- clofibrate
- colestipol
- atenolol
- conjugated equine estrogens
- dalcetrapib
- progesterone
- nifedipine
- enalapril
- folic acid
- insulin glargine
- glimepiride
- calcium
- insulin human
- hydralazine
- icosapent ethyl
- insulin detemir
- magnesium oxide
- iopamidol
- prolycopene
- mipomersen
- moricizine
- nebivolol
- nesiritide
- +36 more
Phase 2 trials (52)
- ringer's lactate
- methylprednisolone
- apl180
- beta carotene
- epoetin
- doxycycline
- fgf-1
- liraglutide
- glucomannan
- l-glutamine
- naltrexone
- hydroxychloroquine
- bone marrow derived mesenchymal stem cells
- cyanocobalamin
- eptifibatide
- tryptophan
- levosimendan
- nitric oxide
- olmesartan
- fondaparinux sodium
- otamixaban
- pactimibe
- pz-128
- nematode anticoagulant protein c2
- rifabutin
- dilmapimod
- vorapaxar
- stem cells
- sulfasalazine
- tocilizumab
- +22 more
Phase 1 trials (9)
Other trials (43)
- montelukast
- norgestrel
- beetroot juice
- benidipine
- exenatide
- esmolol
- danhong
- darapladib
- bq-123
- bq 788
- endothelin-3
- vitis vinifera
- ethinyl estradiol
- ginseng
- leuprolide
- albumin (Human)
- nitroprusside
- cow milk
- phytosterol
- ranolazine
- safflower oil
- sorbitol
- tongmai yangxin
- verapamil
- vitamin k
- voglibose
- arthrospira platensis
- dun ye guan xin ning
- inactivated influenza vaccine
- oat bran
- +13 more
Organizations
Organization Involved with Phase 4 Indications (223)
- AstraZeneca
- Technical University of Munich
- Korea University
- Beijing Anzhen Hospital
- Tel Aviv University
- Innogene Kalbiotech Pte. Ltd
- University of Campinas
- New York University
- Shionogi
- Government of Egypt
- Wake Forest University
- Juntendo University
- Astellas
- People's Liberation Army of China
- Atlanta Heart Specialists, LLC
- Dong-A Pharmaceutical
- IHF GmbH - Institut für Herzinfarktforschung
- University of Athens
- Janssen Pharmaceutica NV
- Yamaguchi University
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- The University of Hong Kong
- Bayer
- Technion University
- University of London
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Forest Laboratories
- Shenyang Northern Hospital
- Johannes Gutenburg University
- Methodist Cancer Center, Houston, Texas
- +193 more
Organization Involved with Phase 3 Indications (159)
- George Washington University
- AtheroGenics
- Wyeth
- Kowa
- National Institutes of Health (NIH)
- Northwestern University
- Boston University
- National Institute on Aging (NIA)
- University of Alabama, Birmingham
- Santa Rosa Medical Center
- Geisinger Clinic
- United States Army
- Chongqing Medical University
- University of California, Berkeley
- Venezuelan Foundation of Heart Failure
- AbbVie
- Pronova BioPharma
- Pontifícia Universidade Católica do Paraná
- University of Montreal
- Washington University in St. Louis
- Gachon University
- University Hospital of North Norway
- Oklahoma Medical Research Foundation
- Palo Alto Medical Research Foundation
- St. Joseph Hospital Health Center
- Dartmouth University
- University of Western Brittany
- Yale University
- University of Michigan
- University of Alberta
- +129 more
Organization Involved with Phase 2 Indications (77)
- Radiant Research
- Xijing Hospital
- Genentech
- University of Tennessee
- Government of Poland
- J. W. Goethe University
- Eisai
- Diagram B.V.
- Mianyang Central Hospital
- MedImmune
- University of Texas at Houston
- University Alicante
- Organon
- The Medicines Company
- Richardson Centre for Functional Foods and Nutraceuticals
- Cardiovascular Imaging Technologies
- Platelet and Thrombosis Research L.L.C
- Ippokratio Hospital Athens
- Jacksonville Center for Clinical Research
- The TIMI Study Group
- Danone Research
- CV Therapeutics
- Universidad de Antioquia
- Uppsala University
- Momenta Pharmaceuticals
- Anthera Pharmaceuticals
- RTI International
- Indiana University
- Biomarin
- University of Helsinki
- +47 more
Organization Involved with Phase 1 Indications (18)
- Precision Medicine
- Canadian Institutes of Health Research (CIHR)
- Shahid Beheshti University of Medical Sciences
- Chang Gung University
- Kuopio University Hospital
- University of Eastern Finland
- AlphaCore Pharma LLC
- Masih Daneshvari Hospital
- Vanderbilt University
- Liuhuaqiao Hospital
- University of Louisville
- CRL/Medinet
- CirQuest Labs
- Honya Medical Inc
- McGill University
- Karolinska Institute
- Cytori Therapeutics
- Lee's Pharmaceutical
Organization Involved with Other Experimental Indications (67)
- Beijing Municipal Health Bureau
- Swiss National Science Foundation
- Utah State University
- Hebrew University
- Henan Institute of Cardiovascular Epidemiology
- New York City Health and Hospitals Corporation
- Shantou University
- Aarhus University
- State Health Center, Budapest, Hungary
- Reliant Pharmaceuticals
- Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region
- Hamilton Health Sciences Corporation
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- University of New Mexico
- University of Tokyo
- University of Tehran
- Nanjing University
- Government of Hungary
- D'Annunzio University of Chieti–Pescara
- Yan'an University Affiliated Hospital
- Fujian Medical University
- University of Geneva
- POM Wonderful LLC
- European Commission
- Xianyang Central Hospital
- General Hospital of Chinese Armed Police Forces
- American Egg Board
- Rio de Janeiro State University
- Julius-Maximilians University
- Fosun
- +37 more